Beam Therapeutics IncEquity-NMS: BEAM
Equity-NMS: BEAM
$24.8
-0.04
(21 May)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$24.80
Open
$24.80
Today’s high
$25.58
Today’s low
$24.63
52W low
$16.95
52W high
$49.5
1Y
-28.01%
PE
-15.17
EPS (TTM)
-1.69
Shares O/S
82.31M
Market cap
2.04B
Insights
No insights found for this stock
Compare with other stock
Price
1D
PE
Market cap
About Beam Therapeutics Inc

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid.

Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate. .


FAQs

Can I buy Beam Therapeutics Inc shares in India?
How to buy Beam Therapeutics Inc shares in India?
What is the share price of Beam Therapeutics Inc?
What is the Market Capitalization of Beam Therapeutics Inc?
What is the PE ratio of Beam Therapeutics Inc?
Is Beam Therapeutics Inc a good stock to buy?
In which sector / industry does Beam Therapeutics Inc operate?